A new Parkinson’s treatment: what tavapadon could mean for everyday life

A new once-daily medication has been approved in the United States to help manage Parkinson’s movement symptoms. It offers another treatment option—but it has not been shown to cure Parkinson’s or slow its progression.

The Michael J. Fox Foundation reports that the US Food and Drug Administration has approved tavapadon, marketed as Juvmo. It can be used alone or alongside levodopa, depending on a person’s treatment needs. Parkinson’s Disease

How does it work?

Parkinson’s involves the loss of brain cells that produce dopamine, a chemical involved in controlling movement.

Tavapadon belongs to a group of medicines called dopamine agonists. These medicines activate dopamine receptors—rather like switching on signals that dopamine would normally provide.

What makes tavapadon different is its selective action on D1 and D5 receptors, compared with the D2 and D3 receptors targeted by many existing dopamine agonists. Researchers hope this approach can provide effective movement control with fewer of certain troublesome side effects. That possibility still needs further investigation. JAMA Network

What did the studies find?

The phase 3 TEMPO studies examined tavapadon in both early Parkinson’s and in people experiencing fluctuations while taking levodopa.

In TEMPO-3, adding tavapadon increased good “on” time by approximately 1.1 hours a day more than adding placebo. “Off” time fell by about one additional hour a day compared with placebo. These were average results; individual responses varied. Sep 28, 2026

“On” time means periods when medication is controlling symptoms reasonably well. “Off” time means periods when symptoms return or become more difficult to manage.

For someone whose day is interrupted by wearing-off, an extra hour of better symptom control could create more opportunity to get dressed, enjoy an outing or spend time with family. These are examples of why the results may matter—not guaranteed outcomes for every person.

Does it have fewer side effects?

Possibly for some side effects, but that has not yet been established through direct comparisons with older dopamine agonists. The Foundation points out that trial duration may also limit what we know about longer-term risks. Parkinson’s Disease

Common reported side effects include nausea, headache and dizziness. The medicine’s safety information also warns about:

• Low blood pressure, particularly when standing.
• Hallucinations.
• New or worsening involuntary movements.
• Unusual urges, including compulsive gambling, shopping, eating or increased sexual urges. Sep 28, 2026

For families and support workers, changes in behaviour deserve attention alongside changes in movement. A treatment’s value depends on how it affects the whole person.

What this news does—and does not—tell us

The trials demonstrate symptom improvement. They do not establish that tavapadon prevents Parkinson’s, repairs damaged brain cells or changes the underlying course of the condition. The early-Parkinson’s trial also identified the need for further evidence on long-term safety and effectiveness. JAMA Network

It is encouraging progress, while leaving important questions about who will benefit most and how it compares with existing treatments.

What about Australia?

FDA approval applies to the United States. It does not establish Australian approval, availability or PBS subsidy. I could not confirm an Australian approval or launch date from the sources checked, so this should be presented to HEAL readers as a US development.

Australians interested in tavapadon can raise it with their neurologist or Parkinson’s nurse. Any medication changes should be guided by the treating team.

The HEAL takeaway

At HEAL, we welcome research that may give people more choice in managing Parkinson’s. Better symptom control can matter because everyday life matters—movement, independence, connection and participation.

The practical message is to stay informed, keep track of symptoms and side effects, and use that information in conversations with the care team. A new treatment adds another possibility to personalised care.

More options bring hope. Understanding both the benefits and limitations helps turn that hope into informed action.

Based on The Michael J. Fox Foundation’s article, with supporting trial and manufacturer information. Checked 10 October 2026.